In this study, we examined (i) levels of circulating TRAIL in patients with increasing NAFLD severity; (ii) NAFLD pathogenesis using murine models of TRAIL-deletion; and (iii) the direct effect of TRAIL in NAFLD in vitro. This evidence concerns the gene TNFSF10 and metabolic dysfunction-associated steatotic liver disease.